Certain prognostic factors, such as larger tumor size (>5 cm), persistence of M-protein, negative CD56 expression, and incomplete response to initial therapy, have been associated with an increased risk of progression and should prompt more intensive monitoring [53,54]. Here, MYOM2 is linked to neoplasm.